Matches in Wikidata for { <http://www.wikidata.org/entity/Q82975981> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- Q82975981 description "article scientifique (publié 2011)" @default.
- Q82975981 description "artikull shkencor i botuar më 01 janar 2011" @default.
- Q82975981 description "artículu científicu espublizáu en xineru de 2011" @default.
- Q82975981 description "scientific article published on 01 January 2011" @default.
- Q82975981 description "wetenschappelijk artikel" @default.
- Q82975981 description "наукова стаття, опублікована в січні 2011" @default.
- Q82975981 name "A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer" @default.
- Q82975981 name "A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer" @default.
- Q82975981 name "A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer" @default.
- Q82975981 type Item @default.
- Q82975981 label "A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer" @default.
- Q82975981 label "A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer" @default.
- Q82975981 label "A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer" @default.
- Q82975981 prefLabel "A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer" @default.
- Q82975981 prefLabel "A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer" @default.
- Q82975981 prefLabel "A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer" @default.
- Q82975981 P1433 Q82975981-7CF5393F-B879-4B44-84F1-07B2B25E87F2 @default.
- Q82975981 P1476 Q82975981-4F2638DC-C4B2-4DB8-8C3D-12355A330D05 @default.
- Q82975981 P2093 Q82975981-0780FE6B-4C0E-4029-9630-9BB37FDF9BA4 @default.
- Q82975981 P2093 Q82975981-0A8A845A-6755-45AF-8783-7F7B100EA19F @default.
- Q82975981 P2093 Q82975981-3D1DB8AB-2354-40F7-A297-B9463193A6F1 @default.
- Q82975981 P2093 Q82975981-406F7A12-CB5D-4B45-B6E4-D507B69E75B6 @default.
- Q82975981 P2093 Q82975981-5245EE18-D527-4E62-95A9-2010458035B7 @default.
- Q82975981 P2093 Q82975981-55A9F570-3BBA-431A-86F8-59171E29A5C3 @default.
- Q82975981 P2093 Q82975981-59959E87-7F60-4A66-8717-552C6675844F @default.
- Q82975981 P2093 Q82975981-8978CE6A-DCAD-47BD-BEDC-FE0D6B030C90 @default.
- Q82975981 P2093 Q82975981-8A48858C-CD26-4A8D-B7AB-BFFCA03204DC @default.
- Q82975981 P2093 Q82975981-9857274D-BC2F-4083-BF52-BFA46879C586 @default.
- Q82975981 P2093 Q82975981-9EF92DEB-0A26-408C-92A2-A9871B25934A @default.
- Q82975981 P2093 Q82975981-ACF53AC0-D35C-4A0E-AF67-39909F96EBDD @default.
- Q82975981 P2093 Q82975981-CA854E20-823C-4422-92F1-99B3DC52C318 @default.
- Q82975981 P304 Q82975981-4F9910E8-F4A7-4006-AF4B-EED6AF406F81 @default.
- Q82975981 P31 Q82975981-FFF90A4A-1E56-40D8-85C8-E2D8BB5D9C56 @default.
- Q82975981 P356 Q82975981-F9F7E51E-5D07-4D06-BD36-E97776180F09 @default.
- Q82975981 P433 Q82975981-A90E2598-7FF0-4B88-81B7-4831DF7E3ACE @default.
- Q82975981 P478 Q82975981-9116DD36-7F99-44E6-81CB-6BB62EB0D7A1 @default.
- Q82975981 P50 Q82975981-0F3244DE-7BBC-4968-8009-505E8379AC5F @default.
- Q82975981 P50 Q82975981-58DE1CAC-A840-4A18-932B-1BB6717EC37B @default.
- Q82975981 P577 Q82975981-0107D57F-3AA4-44B9-9B25-9A6A87ED6878 @default.
- Q82975981 P698 Q82975981-A82CC675-5CE7-402E-8190-97EE646B5EBB @default.
- Q82975981 P921 Q82975981-0864D950-7E64-4D23-BB42-D4D26C2CF4A4 @default.
- Q82975981 P921 Q82975981-9C0C1751-522E-457E-983A-A35961F19D65 @default.
- Q82975981 P356 0284186X.2010.535847 @default.
- Q82975981 P698 21174610 @default.
- Q82975981 P1433 Q326164 @default.
- Q82975981 P1476 "A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer" @default.
- Q82975981 P2093 "Dagny Pettersson Skøld" @default.
- Q82975981 P2093 "Elisabet Lidbrink" @default.
- Q82975981 P2093 "Henrik Lindman" @default.
- Q82975981 P2093 "Jonas Bergh" @default.
- Q82975981 P2093 "Kenneth Villman" @default.
- Q82975981 P2093 "Lena Carlsson" @default.
- Q82975981 P2093 "Martin Søderberg" @default.
- Q82975981 P2093 "Mats Hellstrøm" @default.
- Q82975981 P2093 "Nils-Olof Bengtsson" @default.
- Q82975981 P2093 "Per Edlund" @default.
- Q82975981 P2093 "Per Karlsson" @default.
- Q82975981 P2093 "Sara Margolin" @default.
- Q82975981 P2093 "Scandinavian Breast Group Study SBG 2004-1" @default.
- Q82975981 P304 "35-41" @default.
- Q82975981 P31 Q13442814 @default.
- Q82975981 P356 "10.3109/0284186X.2010.535847" @default.
- Q82975981 P433 "1" @default.
- Q82975981 P478 "50" @default.
- Q82975981 P50 Q58469511 @default.
- Q82975981 P50 Q58901797 @default.
- Q82975981 P577 "2011-01-01T00:00:00Z" @default.
- Q82975981 P698 "21174610" @default.
- Q82975981 P921 Q18936 @default.
- Q82975981 P921 Q420436 @default.